Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2

X
Trial Profile

Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varlitinib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals; PharmaNet Development Group
  • Most Recent Events

    • 08 Aug 2013 According to an Array BioPharma media release, positive results of this trial were reported in gastric cancer and a phase 2b study will be conducted.
    • 07 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01614522).
    • 07 Jun 2012 Company (ASLAN Pharmaceuticals) and additional lead trial investigator (Lee KW) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top